Air Liquide enters exclusive negotiations with EQT for the sale of schülke

Paris, France, April 7, 2020

Air Liquide announced today that it has entered into exclusive negotiations with EQT, a global investment organization, for the potential sale of its subsidiary Schülke & Mayr GmbH, a global leader in infection prevention and hygiene.

This potential sale, as previously announced in November 2019,  illustrates Air Liquide’s strategy to review its business portfolio regularly and to focus on its core gases and healthcare businesses, thereby enhancing Air Liquide’s performance.

Air Liquide intends to continue to develop its healthcare activities, while providing Schülke & Mayr GmbH with the best opportunity for its long-term development.

If completed, the acquisition by EQT VIII fund will further support Schülke & Mayr GmbH’s next phase of growth and its innovation development.

This transaction is subject to the final and definitive agreement between the parties, and will be carried out in the framework of the relevant social processes including ongoing dialogue with the employee representatives’ bodies. Furthermore, the transaction will be subject to antitrust and foreign investment clearances.

Schülke & Mayr GmbH, headquartered in Germany, is a leader in infection prevention and hygiene for more than 130 years. schülke develops, produces and distributes antiseptics for wound care, disinfectants, medical and cosmetic skin care products and preservatives. The company offers its customers innovative products, technologies and services in its core business fields:  Healthcare, Industrial Hygiene and Personal Care. schülke’s mission is to protect lives worldwide and therewith actively contributes to patient safety. Today, the company employs over 1,250 employees worldwide and sells its products in over 100 countries. Represented by 22 subsidiaries, schülke operates three production sites in Germany (schülke), France (Bioxal) and Brazil (Vic Pharma).

EQT is a differentiated global investment organization with more than EUR 62 billion in raised capital and around EUR 40 billion in assets under management across 19 active funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 27 billion and approximately 159,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.